Our Board of Directors is responsible for the overall strategy and performance of Salix Pharmaceuticals. Elected annually by our shareholders, the Board is comprised of executive and nonexecutive members.
Randy W. Hamilton
Mr Hamilton is a Founder of Salix Pharmaceuticals, Inc, and served as Chairman of the Board, President, and Chief Executive Officer from the company's inception through November 1999. He remained Executive Chairman of the Board until June 2002. Before founding Salix, Mr Hamilton was Manager of Business Development at California Biotechnology, Inc (now Scios, Inc), and responsible for the commercial aspects of several of the company's development projects, including human lung surfactant, drug delivery systems, genetic marker diagnosis, and growth factors. He also was responsible for establishing strategic relationships with the Japanese pharmaceutical industry. Before joining California Biotechnology, Mr Hamilton was Director of Strategic Planning and Business Development at SmithKline Diagnostics, then a division of SmithKline Beckman, where he also held positions in Market Research and Marketing Information Services. Mr Hamilton received a BA in Sociology from California State University, Long Beach.
Lorin K. Johnson, PhD
Founder and Chief Scientific Liaison
Dr Johnson is a Founder of Salix and serves as Chief Scientific Liaison, and is an active member of the Salix Business development team. Previously, Dr Johnson served as Senior Vice President and Chief Scientific Officer (1999-2002) and was Vice President of Research and a member of the Salix Board of Directors (inception to 2000). Prior to founding Salix, Dr Johnson served as Director of Scientific Operations and Chief Scientist at California Biotechnology, Inc, (Scios, Inc), where he headed research on antiinflammatory therapeutics targeting secretory phospholipase A2. Before joining California Biotechnology, Dr Johnson was an Assistant Professor of Pathology at Stanford University Medical Center. Dr Johnson received his BS and PhD in Molecular Biology from the University of Southern California and was a postdoctoral fellow at the University of California, San Francisco, researching molecular mechanisms of corticosteroid action. Dr Johnson is the coauthor of 75 journal articles and book chapters and is the coinventor on 18 issued patents.
Board of Directors
John F. Chappell
Mr Chappell has served as a member of the Salix Board of Directors since December 1993 and served as Chairman of the Board from September 2003 to June 2010. From 1990 until his retirement in 2002, he served as Founder and Chairman of Plexus Ventures LLC, a private company that specializes in business development and strategic transactions for clients in the biotechnology, pharmaceutical, and drug delivery industries. Prior to founding Plexus Ventures LLC, Mr Chappell served as Chairman, Worldwide Pharmaceuticals, at SmithKline Beecham plc, now GlaxoSmithKline plc, or GSK, where he was responsible for the multibillion dollar ethical pharmaceutical business with 30,000 employees worldwide. During his 28 years at SmithKline Beecham, Mr Chappell also headed the International Consumer Products (OTC) operations and Corporate Planning and Development. He has served on the Board of Directors at SmithKline Beecham, the Pharmaceutical Manufacturers Association (now PhRMA), the Industrial Biotechnology Association (now BIO), and Main Line Health. Mr Chappell holds a BA from Harvard University and attended the Wharton School of the University of Pennsylvania.
Among other qualifications, attributes, and skills, Mr Chappell's knowledge and experience in leading large organizations in the life sciences industry, being the founder and chairman of a company specializing in business development and strategic transactions for companies in the pharmaceutical industry, and serving on boards of directors at pharmaceutical and biotech industry organizations led to the conclusion of our Nominating/Corporate Governance Committee and full Board that he should serve as a Director of our Company in light of our business and structure.
Thomas W. D'Alonzo
Chairman of the Board and Acting Chief Executive Officer
Thomas W. D'Alonzo has served as a member of our Board of Directors since May 2000 and has been the Chairman of the Board since June 2010. Mr D’Alonzo was named Acting Chief Executive Officer in February 2015. From March 2007 to February 2009, Mr D'Alonzo served as the Chief Executive Officer and a director of MiMedx Group, Inc. From May 2006 to April 2007, Mr D'Alonzo was Chief Executive Officer of DARA BioSciences, Inc, a pharmaceutical company, and he served on its Board of Directors from September 2005 to December 2008. From 2000 to 2007, Mr D'Alonzo acted as an independent consultant. Prior to that, from 1996 to 1999, Mr D'Alonzo served as President and Chief Operating Officer of Pharmaceutical Product Development (PPD), Inc, a global provider of discovery and development services to pharmaceutical and biotechnology companies. Before joining PPD, from 1993 to 1996, he served as President and Chief Executive Officer of GenVec, Inc, a clinical-stage biopharmaceutical company. From 1983 to 1993, Mr D'Alonzo held positions of increasing responsibility within Glaxo, Inc, the US division of GlaxoSmithKline plc, including President. Mr D'Alonzo received a BS in Business Administration from the University of Delaware and his J.D. from the University of Denver College of Law.
Among other experience, qualifications, attributes and skills, Mr D'Alonzo's knowledge and experience in legal matters, in leading large organizations and serving on boards of directors in the life sciences industry led to the conclusion of our Nominating/Corporate Governance Committee and of our full Board that he should serve as a director of our Company in light of our business and structure.
William P. Keane
Mr Keane joined the Salix Board of Directors in January 2004. From June 2007 to January 2010, Mr Keane served on the Board of Directors of Intellect Neurosciences, Inc. From October 2002 until September 2005, Mr Keane was Chief Financial Officer and Corporate Secretary for Genta, Inc, a biopharmaceutical company focused on the identification, development, and commercialization of drugs for the treatment of patients with cancer. Prior to that, Mr Keane was Vice President, Sourcing, Strategy and Operation Effectiveness, for Bristol-Myers Squibb Company from April 2001 until October 2002. From August 2000 until April 2001, Mr Keane was Chief Financial Officer for Covance Biotechnology Services, now known as Fujifilm Diosynth Biotechnologies, a drug development services company. From September 1997 until July 2000, Mr Keane was Vice President, Finance and Global Pharmaceutical Manufacturing, for Warner-Lambert Company, a pharmaceutical company subsequently acquired by Pfizer, Inc. From 1985 to 1997, Mr Keane held several positions at Ciba-Geigy/Novartis, including positions in Switzerland and the United Kingdom. Mr Keane received a BA in Microbiology from Rutgers College and an MBA in Finance from the Rutgers University School of Management.
Among other qualifications, attributes, and skills, Mr Keane's experience in accounting and auditing matters affecting the life sciences industry led to the conclusion of our Nominating/Corporate Governance Committee and full Board that he should serve as a Director of our Company in light of our business and structure.
Mark A. Sirgo, PharmD
Dr Sirgo joined the Salix Board of Directors in February 2008. Since July 2005, Dr Sirgo has been President and Chief Executive Officer of BioDelivery Sciences International, Inc (NASDAQ: BDSI), a specialty pharmaceutical company, and has served in various executive positions and as Director of the company since August 2004. Prior to this position, Dr Sirgo was Cofounder and Chief Executive Officer of Arius Pharmaceuticals, Inc, which was acquired by BDSI in August 2004. Prior to his involvement with Arius, Dr Sirgo spent 3 years as Senior Vice President, Global Sales and Marketing, at Pharmaceutical Product Development, Inc, and 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GSK, including Vice President of International OTC Development and Vice President of New Product Marketing. Dr Sirgo received a BS in Pharmacy from The Ohio State University and a PhD from the Philadelphia College of Pharmacy and Science.
Among other qualifications, attributes, and skills, Dr Sirgo's knowledge and experience in drug development, clinical trials, and regulatory processes led to the conclusion of our Nominating/Corporate Governance Committee and full Board that he should serve as a Director of our Company in light of our business and structure.